Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

News and Events

For additional information, please contact info@trovagene.com. or call 1-858-952-7593

Please see write-up on Trovagene by CNA. Click Here to Read Article